GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Aphria

Cronos Group

GrowGeneration Corp

Tilray Brands

Village Farms International

These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and best performance for October.

Top Marijuana Stocks on the NASDAQ for October 2020

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Innovative Industrial Properties

Trulieve Cannabis Corp.

These cannabis stocks are ready to show investors the green.

10 Pot Stocks Expected to Be Profitable in 2021

The stock has fallen more than 20% in just the past three months.

GW Pharmaceuticals: Buy the Dip?

This represents the third successful regulatory approval globally for GW’s plant-derived cannabis-based medicine This represents the third successful regulatory approval globally for GW’s plant-derived cannabis-based medicine

GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

Morgan Stanley

GW Pharmaceuticals plc (GWPH) CEO Justin Gover Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

- Results from post-hoc analysis of phase 3 clinical study show nabiximols was well-tolerated and provided continued reductions in spasticity for individuals who remained on therapy

Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020

- Nearly one-third of survey respondents indicated use of THC-containing cannabis for Multiple Sclerosis (MS) symptom management - Nearly one-third of survey respondents indicated use of THC-containing cannabis for Multiple Sclerosis (MS) symptom management

Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020

OrganiGram Holdings Inc.

Investors will want to preserve their hard-earned capital by staying away from these marijuana companies for now.

3 Cannabis Stocks to Avoid Like the Plague in September

LONDON, Sept.  10, 2020  (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve as a member of the Audit Committee. Mr. Gryska brings valuable global pharmaceutical and biotechnology industry experience and executive-level financial leadership to GW’s Board.

GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors

In a complicated legal landscape, one FDA-approved cannabis product can help investors pick the winner.

Better Cannabis Stock: Charlotte's Web vs. GW Pharmaceuticals

LONDON and CARLSBAD, Calif., Sept.  01, 2020  (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the following virtual investor conferences:

GW Pharmaceuticals to Present at Upcoming Investor Conferences

Amplify Seymour Cannabis ETF

Amplify Alternative Harvest ETF

Global X Cannabis ETF

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Pure Cannabis ETF 

Unpacking Terpenes & Cannabinoids (Podcast Transcript)

Shares of the only producer of FDA-approved CBD have tumbled this summer.

Can GW Pharmaceuticals Stock Bounce Back?

Amyris

These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and best performance for September.

Top Marijuana Stocks on the NASDAQ for September 2020

GW Pharmaceuticals: A Buy After Stock Price Decline

Unpacking Terpenes & Cannabinoids (Podcast)

AbbVie

You can find the best marijuana stocks to buy by considering their revenue rather than chasing pure hype. Here are six that fit the bill.

6 Marijuana Stocks to Buy That Are Sticking In the Green

The green rush was in full force for some top-notch money managers in the second quarter.

3 Cannabis Stocks Billionaires Were Buying in Q2

Regeneron Pharmaceuticals

Here's why these recession-proof stocks are great buy-and-hold opportunities for the long term.

2 Top Pharma Stocks to Buy in August

Limitless Potential Of Cannabis (Podcast Transcript)

Limitless Potential Of Cannabis Plant (Podcast)

Arena Pharmaceuticals

Scotts Miracle-Gro

Zynerba Pharmaceuticals

Exploring more about medical/pharma side of cannabis sector and thematic ETF investing.

Pharma Medical Cannabis More Robust And Resilient (Podcast Transcript)

A new Canadian study could have ramifications for the entire marijuana industry.

The Cannabis Industry Needs Hard Data on Medical Marijuana. This Study Could Provide It

The company's latest set of quarterly figures was a buzzkill for investors.

Why GW Pharmaceuticals Crashed 17% on Friday

Shares of GW Pharmaceuticals PLC GWPH, -11.71% slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coronavirus pandemic.

News for GW Pharmaceuticals Stock (GWPH)